Further limitations of this study are that clinical data associated with the proteomic data were not available, the criteria for AD diagnosis and cognitive norm were evaluated according to the labels provided by the original study only, information about key factors such as the subjects’ APOE ε4 genotype could not be accounted for, and measurements of Aβ and Tau peptides were not available to be able to make comparisons. The gene discussed is MAPT; the disease is Alzheimer disease.